

NAFLD SUMMIT 2018

20 - 22 SEPTEMBER 2018
GENEVA, SWITZERLAND

Scientific Organising Committee

Prof. Elisabetta Bugianesi, *Italy*

Prof. Philip N. Newsome, *United Kingdom*

Prof. Vlad Ratziu, *France*



**SPONSORSHIP
OPPORTUNITIES**

Supported by AbbVie, Bristol-Myers Squibb and MSD who provided funding.

AbbVie | Bristol-Myers Squibb | MSD

Other sponsors:

Boehringer Ingelheim | Genfit | Gilead | Intercept | Pfizer

None have had an input into the content of the materials and presentations used at this event.



www.easl.eu

KEY MEDIA INFORMATION

Location:

Starling Hotel & Conference Centre
Route Francois-Peyrot 34
1218 Le Grand-Saconnex
Geneva

Website: The latest Conference programme, speakers and supporting documents will be posted and updated at <http://www.easl.eu/nafld2018/>.

Webcast: A post-Conference debrief will be shared through the EASL YouTube channel: EASLEurope.

Multimedia: Conference posters, banners, and selected photographs of the Conference will be available on the conference website along with other multimedia materials, at <http://www.easl.eu/nafld2018/>. Key photos from the conference will be shared through EASL social media accounts in real-time.

www.twitter.com/EASLnews

www.facebook.com/EASLnews

Social media hashtag: **#NAFLDsummit**

Press releases: One pre-conference press release will be shared by email and via EurekAlert.

MULTIMEDIA



EASL | SUMMIT
The Home of Hepatology

NAFLD SUMMIT 2018

20 - 22 SEPTEMBER 2018
GENEVA, SWITZERLAND

Scientific Organising Committee
Prof. Elisabetta Bugianesi, *Italy*
Prof. Philip N. Newsome, *United Kingdom*
Prof. Vlad Ratziu, *France*

Supported by AbbVie, Bristol-Myers Squibb and MSD who provided funding.
AbbVie | Bristol-Myers Squibb | MSD

Other sponsors:
Boehringer Ingelheim | Genfit | Gilead | Intercept | Pfizer
None have had an input into the content of the materials and presentations used at this event.

SPONSORSHIP OPPORTUNITIES

f in +

www.easl.eu

[Download conference poster](#)

EASL NAFLD SUMMIT II 2018

Preliminary Programme

Thursday 20 September

Welcome and introductory remarks

13:55 - 14:00 | Chairs:
Philip NEWSOME, *United Kingdom*
Frank TACKE, *Germany*

The clinical picture of NAFLD/NASH

Chairs:
Elisabetta BUGIANESI, *Italy*
Zobair YOUNOSSI, *United States*

14:00 - 14:25 | **Global overview of obesity and population strategies to tackle it**
Harry RUTTER, *United Kingdom*

14:25 - 14:50 | **Health care burden of NAFLD and NASH**
Jacob GEORGE, *Australia*

14:50 - 15:15 | **Paediatric NAFLD: the future burden of NASH including the risk of HCC linked to obesity during childhood**
Valerio NOBILI, *Italy*

15:15 - 15:40 | **Natural history and use of large data to risk stratify**
Quentin ANSTEE, *United Kingdom*

15:40 - 15:55 | **The current policy on NAFLD in Europe - results from the EILF NAFLD policy review**
Frank TACKE, *Germany*

15:55 - 16:25 | **Round-table discussion - What are the new challenges? What policies should we encourage?**

16:25 - 17:00 | **ePoster Session 1 and Coffee Break**

Case-finding for NAFLD/NASH

Chairs:
Guangsheng AITHAL, *United Kingdom*
Hannele YK-JÄRVINEN, *Finland*

Multidisciplinary board:
Jerome BOURSIER, *France*
Roy TAYLOR, *United Kingdom*
Emmanuel TSOCHATZIS, *United Kingdom*

17:00 - 17:10 | **Clinical Case I - how do cases present in the community* Exemplar case illustrating challenge how to decide which patients need specialist input**
Emmanuel TSOCHATZIS, *United Kingdom*

17:10 - 17:35 | **Case identification in diabetes clinics: where do we stand so far?**
Roy TAYLOR, *United Kingdom*

17:35 - 17:45 | **Clinical Case II - evolution of identified case + use of non-invasive modalities**
Emmanuel TSOCHATZIS, *United Kingdom*

17:45 - 18:10 | **Promises and limits of non-invasive methods in NASH**
Jerome BOURSIER, *France*

[Download conference programme](#)

The conference was financially supported by: AbbVie, Bristol-Myers Squibb, and MSD. Additional conference sponsors include: Boehringer Ingelheim, Genfit, Gilead, Intercept, and Pfizer.

PRESS RELEASE

EASL Nonalcoholic Fatty Liver Disease Summit: Uniting clinicians, experts, and industry

EMBARGOED UNTIL: 20 September 2018, 07:00 CET

Geneva, Switzerland, 20 September 2018 - The EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit commenced today at the Starling Hotel Conference Centre in Geneva, Switzerland, attended by over 300 basic and clinical researchers, industry, and renowned specialists from around the world.

NAFLD is the leading cause of chronic liver disease not only in Western countries but also among developing countries in, East Asia, South Asia, the Middle East, and Latin America. In the US and Europe, nearly 40% of the population have NAFLD and approximately 20% of these individuals are likely to develop progressive liver disease (i.e., NASH) that lead to liver fibrosis and cirrhosis. Another emerging challenge is hepatocellular cancer which increasingly arises in pre-cirrhotic stages.

Although a significant number of new drugs are already in the development pipeline, none are as yet, approved by regulatory agencies. As such, the identification and development of new therapies are urgently needed.

The three day conference is the second NAFLD summit but for the first time it will feature a number of different sessions or 'case conferences' where key issues in the management of patients will be discussed. Multidisciplinary representation was integral to the structuring of the Summit programme due to the fact that NAFLD is a disease that affects various organs and systems.

[NAFLD track related content and projects:](#)

[EASL NAFLD Clinical Practice Guidelines – slide decks](#)

[EASL website content on NASH/NAFLD](#)

[LITMUS](#)

EASL is the dissemination arm of an EU funded project titled Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS), funded by the European Innovative Medicines Initiative 2 Joint Undertaking, also brings together clinicians and scientists from prominent academic centres across Europe with companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA). Their common goals are developing, validating and qualifying better biomarkers for testing NAFLD.

The conference was financially supported by: AbbVie, Bristol-Myers Squibb, and MSD. Additional conference sponsors include: Boehringer Ingelheim, Genfit, Gilead, Intercept, and Pfizer.

For any additional press related questions/comments, contact: Hyatt Antognini-Amin,
PR & Media Coordinator
press@easloffice.eu



The conference was financially supported by: AbbVie, Bristol-Myers Squibb, and MSD. Additional conference sponsors include: Boehringer Ingelheim, Genfit, Gilead, Intercept, and Pfizer.